A single centre, randomised, placebo-controlled phase I trial of PSA-oxyntomodulin in healthy volunteers
Latest Information Update: 19 May 2014
At a glance
- Drugs Oxyntomodulin (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- 19 May 2014 New trial record
- 12 May 2014 Results reported in a Xenetic Biosciences media release.